Download MendeleyDiscovery and Characterization of PVTX-321 as a Potent and Orally Bioavailable Estrogen Receptor Degrader for ER+/HER2- Breast Cancer.
Xu, G., Havens, C.G., Deng, Q., Lowenstein, C., Samanta, D., Vidal, B., Behshad, E., Russell, M., Orth, P., Rice, C.T., Nagilla, R., Kirchhoff, P., Chen, Z., Rej, R.K., Acharyya, R.K., Wu, D., Wang, S., Zhang, W., Wu, W., Jolivette, L., Strickland, C., Sui, Z., Mohammad, H.P., Zhang, X., Priestley, E.S.(2025) J Med Chem 68: 11299-11321
- PubMed: 40366756
- DOI: https://doi.org/10.1021/acs.jmedchem.5c00223
- Primary Citation of Related Structures:
9ODR, 9ODS - PubMed Abstract:
Estrogen receptor α (ERα) is a key therapeutic target in ER+/HER2- breast cancer, but ESR1 mutations drive resistance to endocrine therapies. Heterobifunctional degraders (HBDs) targeting ERα offer a promising strategy to overcome this resistance. Here, we report PVTX-321 ( 16a ), a potent ER HBD derived from a novel spirocyclic cereblon ligand and an ERα binder. PVTX-321 achieves a DC 50 of 0.15 nM in MCF-7 cells and acts as a strong antagonist (IC 50 = 59 nM), suppressing proliferation in ERα+ cell lines, including mutant variants (Y537S, D538G). It demonstrates favorable oral bioavailability, dose-dependent ERα degradation in vivo and induces tumor regression at 10 mg/kg (QD) in MCF-7 xenografts. With minimal CYP inhibition and a strong preclinical safety profile, PVTX-321 is a promising candidate for advancing ER+/HER2- breast cancer treatment.
- SK Life Science Laboratories, 2500 Renaissance Boulevard, King of Prussia, Pennsylvania 19406, United States.
Organizational Affiliation:
